Physician profile
John Howard Rex
NPI 1306151162
$63,498.16
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $21K · 2020: $3,750 · 2021: $13K · 2022: $5,200 · 2023: $15K · 2024: $5,642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,720 · Food and Beverage: $60.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $16,032.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,720.00 |
| Food and Beverage | $60.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $19,331.06 | 2019-2024 | |
| F. Hoffmann-La Roche Ag | $16,481.02 | 2019 | |
| Glaxosmithkline, LLC. | $11,200.00 | 2021-2022 | |
| Pfizer INC. | $8,904.00 | 2020-2021 | |
| Biomerieux INC | $5,582.08 | 2024 | |
| Sumitomo Pharma Co., LTD. | $2,000.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rex listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.